OBJECT DRUGS

• Metoclopramide (Reglan, etc.)

PRECIPITANT DRUGS

Enzyme Inhibitors:

• Abiraterone (Zytiga)
• Amiodarone (Cordarone, etc.)
• Cimetidine (Tagamet, etc.)
• Cinacalcet (Sensipar)
• Clobazam (Onfi)
• Diphenhydramine (Benadryl, etc.)
• Haloperidol (Haldol)
• Mirabegron (Myrbetriq)
• Propafenone (Rythmol, etc.)
• Propoxyphene*
• Quinidine (Quinidex)
• Ritonavir (Norvir)
• Terbinafine (Lamisil, etc.)
• Thioridazine (Mellaril)

* Propoxyphene (Darvon) was withdrawn from the US market.

Comment:

Inhibitors of CYP2D6 reduce the metabolism of metoclopramide. Accumulation of metoclopramide may increase the risk of tardive dyskinesia and other movement disorders. Patients with renal disease may be at increased risk.

Class 3: Assess Risk & Take Action if Necessary

• Monitor: Monitor for movement disorders if metoclopramide is administered with a CYP2D6 inhibitor.